Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Breast Neoplasms 10Pancreatic Neoplasms 8Colorectal Neoplasms 8Rectal Neoplasms 7Neoplasm Metastasis 4Colorectal Cancer Metastatic 4Stomach Neoplasms 3Ovarian Neoplasms 3Colonic Neoplasms 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Gallbladder Neoplasms 2Carcinoma, Merkel Cell 2Biliary Tract Neoplasms 2Zollinger-Ellison Syndrome 1Vipoma 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Somatostatinoma 1Sarcoma 1Prostatic Neoplasms 1Pheochromocytoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1

Interventions

gallium Ga 68 dotatate 2veliparib 1telotristat ethyl 1Temozolomide 1Panitumumab 1Octreotide 1Capecitabine 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoid Tumor × Capecitabine × Clear all
NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡